¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"giant platelet"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® platelet ÇÑ±Û Ç÷¼ÒÆÇ
¼³¸í   
  °ñ¼öÀÇ °Å´ë ¼¼Æ÷ÀΠ°Å´ëÇÙ¼¼Æ÷ÀÇ ¼¼Æ÷Áú ÀϺΰ¡ ¶³¾îÁ®¼­ ¼øÈ¯ Ç÷¾× Áß¿¡ ÃâÇöÇÑ °ÍÀ¸·Î Á÷°æÀÌ 2~4¥ìmÀÇ ÀÛÀº °ú¸³Ã¼ÀÌ´Ù. Ç÷¼ÒÆÇÀº ¼Õ»óÀ» ÀÔÀº Ç÷°üÀÇ ³ëÃâµÈ °áÇÕ Á¶Á÷¿¡ ºÙ¾î ¿©·¯ ¹°ÁúÀ» ºÐºñÇÏ¿© ÁöÇ÷ ¹× Ç÷¾× ÀÀ°í¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • mean platelet volume
    Æò±ÕÇ÷¼ÒÆÇ¿ëÀû
  • platelet
    Ç÷¼ÒÆÇ
  • platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ
  • platelet adhesion
    Ç÷¼ÒÆÇºÎÂø
  • platelet agglutination
    Ç÷¼ÒÆÇÀÀÁý
  • platelet aggregation
    Ç÷¼ÒÆÇÀÀÁý
  • platelet concentrate
    Ç÷¼ÒÆÇ³óÃ๰
  • platelet demarcation membrane
    Ç÷¼ÒÆÇ±¸È¹¸·
  • platelet factor 3
    Ç÷¼ÒÆÇÀÎÀÚ3
  • platelet factor 4
    Ç÷¼ÒÆÇÀÎÀÚ4
  • platelet sequestration
    Ç÷¼ÒÆÇ°Ý¸®
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • platelet-specific antigen
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • random donor platelet
    ¹«ÀÛÀ§ÇåÇ÷ÀÚÇ÷¼ÒÆÇ
  • single donor platelet
    ÀÏÀÎÇåÇ÷ÀÚÇ÷¼ÒÆÇ, ÀÏÀΰøÇ÷ÀÚÇ÷¼ÒÆÇ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • giant breast
    °Å´ëÀ¯¹æ
  • giant
    °ÅÀÎ, °Å´ë-
  • giant cell pneumonia
    °Å´ë¼¼Æ÷Æó·Å
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾
  • platelet adhesion
    Ç÷¼ÒÆÇºÎÂø
  • platelet aggregation
    Ç÷¼ÒÆÇÀÀÁý
  • platelet-specific antigen
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • platelet concentrate
    Ç÷¼ÒÆÇ³óÃ๰
  • platelet function disorder
    Ç÷¼ÒÆÇ±â´ÉÀÌ»ó
  • platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • platelet
    Ç÷¼ÒÆÇ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • platelet adhesion
    Ç÷¼ÒÆÇºÎÂø
  • platelet agglutination
    Ç÷¼ÒÆÇÀÀÁý
  • platelet aggregation
    Ç÷¼ÒÆÇÀÀÁý
  • platelet-specific antigen
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • platelet count
    Ç÷¼ÒÆÇ°è»ê
  • platelet function disorder
    Ç÷¼ÒÆÇ±â´ÉÀÌ»ó
  • platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • mean platelet volume
    Æò±ÕÇ÷¼ÒÆÇ¿ëÀû
  • platelet demarcation membrane
    Ç÷¼ÒÆÇ±¸È¹¸·
  • platelet
    Ç÷¼ÒÆÇ
  • platelet refractoriness
    Ç÷¼ÒÆÇºÒÀÀÈ­
  • platelet sequestration
    Ç÷¼ÒÆÇ°Ý¸®
  • platelet immunologic refractory state
    Ç÷¼ÒÆÇ¸é¿ªºÒÀÀ»óÅÂ
  • random donor platelet
    ´ÙÀÎÇåÇ÷Ç÷¼ÒÆÇ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Grey platelet syndrome
    ±×·¹ÀÌÇ÷¼ÒÆÇÁõÈıº
  • MPV => mean platelet volume
    Æò±ÕÇ÷¼ÒÆÇ¿ëÀû
  • PAF =platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ.
  • PAF= platelet activating factor
    Ç÷¼ÒÆÇ Ȱ¼ºÀÎÀÚ.
  • granulocyte-platelet-lymphocyte antigens
    °ú¸³±¸Ç÷¼ÒÆÇ¸²ÇÁ±¸Ç׿ø
  • hellp(hemolysis, elevated liver enzymes, low platelet),heliminths
    À±Ãæ(ëÌõù)
  • hemorrhagic diathesis,defective platelet function
    Ç÷¼ÒÆÇ±â´É°á¼Õ(úìá³÷ùѦÒöÌÀáß)
  • platelet
    Ç÷¼ÒÆÇ(úìá³÷ù).
  • platelet
    Ç÷¼ÒÆÇ(úìá³÷ù)
  • platelet
    Ç÷¼ÒÆÇ
  • platelet activating factor
    Ç÷¼ÒÆÇ Ȱ¼º ÀÎÀÚ
  • platelet adhesion
    Ç÷¼ÒÆÇºÎÂø
  • platelet agglutination
    Ç÷¼ÒÆÇÀÀÁý
  • platelet aggregation
    Ç÷¼ÒÆÇÀÀÁý
  • platelet agitator
    Ç÷¼ÒÆÇÈ¥ÇÕ±â
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • blood disc =b. platelet
    Ç÷¼ÒÆÇ(Ì´ËÛ̬).
  • blood platelet =thrombocyte
    Ç÷¼ÒÆÇ(úìá³÷ù).
  • direct platelet count
    Á÷Á¢Ç÷¼ÒÆÇ°è»ê(¹ý)(?Ì´ËÛ̬˭Ë×ËÑ).
  • granulocyte-platelet-lymphocyte antigens
    °ú¸³±¸Ç÷¼ÒÆÇ¸²ÇÁ±¸Ç׿ø
  • hellp(hemolysis, elevated liver enzymes, low platelet),heliminths
    À±Ãæ(ëÌõù)
  • hemorrhagic diathesis,defective platelet function
    Ç÷¼ÒÆÇ±â´É°á¼Õ(úìá³÷ùѦÒöÌÀáß)
  • human platelet antigens=HPA
    ÀÎÇ÷¼ÒÆÇÇ׿ø
  • mean platelet volume
    Æò±ÕÇ÷¼ÒÆÇ¿ëÀû
  • mean platelet volume=MPV
    Æò±ÕÇ÷¼ÒÆÇ¿ëÀû
  • paf(platelet activating factor)
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ(úìá³÷ù üÀàõì×í­)
  • platelet
    Ç÷¼ÒÆÇ
  • platelet
    Ç÷¼ÒÆÇ(úìá³÷ù).
  • platelet
    Ç÷¼ÒÆÇ(úìá³÷ù)
  • platelet activating factor
    Ç÷¼ÒÆÇ Ȱ¼º ÀÎÀÚ
  • platelet adhesion
    Ç÷¼ÒÆÇºÎÂø
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Thrombocyte [Blood platelet]
    Ç÷¼ÒÆÇ
    [¿¾ ¿ë¾î] Ç÷¼ÒÆÇ
  • Thrombocyte [Blood platelet]
    Ç÷¼ÒÆÇ
    [¿¾ ¿ë¾î] Ç÷Àü¼¼Æ÷
  • Giant
    °ÅÀÎ
    [¿¾ ¿ë¾î] °ÅÀÎ
  • Acromegalic giant
    ¸»´Üºñ´ë°ÅÀÎ
    [¿¾ ¿ë¾î] ¸»´Üºñ´ë°ÅÀÎ
  • Multinuclear giant cell
    ¹µÇÙ°Å´ë¼¼Æ÷
    [¿¾ ¿ë¾î] ´ÙÇÙ¼º°Å´ë¿µ¾ç¸·¼¼Æ÷
  • Trophoblastic giant cell
    ¿µ¾ç¸·°Å´ë¼¼Æ÷
    [¿¾ ¿ë¾î] °Å´ë¿µ¾ç¸·¼¼Æ÷
  • Intravascular giant cell
    Ç÷°ü¼Ó°Å´ë¼¼Æ÷
    [¿¾ ¿ë¾î] Ç÷°ü³»°Å´ë¿µ¾ç¸·¼¼Æ÷
  • Uninuclear giant cell
    ȬÇÙ°Å´ë¼¼Æ÷
    [¿¾ ¿ë¾î] ´ÜÇÙ¼º°Å´ë¿µ¾ç¸·¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • giant chromosome
    °Å´ë ¿°»öü(ËÝÓÞæøßäô÷)
  • giant messenger-like RNA
    °Å´ë(ËÝÓÞ) À¯»çÀü·É(×¾ÞÄîîÖµ) RNA
  • giant RNA
    °Å´ë(ËÝÓÞ) RNA
  • blood platelet
    Ç÷¼ÒÆÇ(úìá³÷ù)
  • platelet
    Ç÷¼ÒÆÇ(úìá³÷ù)
  • platelet-activating factor
    Ç÷¼ÒÆÇȰ¼º ÀÎÀÚ(úìá³÷ùüÀàõì×í­)
  • platelet cofactor I
    Ç÷¼ÒÆÇ(úìá³÷ù) º¸ÀÎÀÚ (ÜÍì×í­) I
  • platelet cofactor II
    Ç÷¼ÒÆÇ(úìá³÷ù) º¸ÀÎÀÚ(ÜÍì×í­) II
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡(úìá³÷ùë¦ÕÎ) ¼ºÀåÀÎÀÚ(à÷íþì×í­)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • platelet
    Ç÷¼ÒÆÇ
  • giant cell
    °Å¼¼Æ÷
  • giant cell tumor
    °Å¼¼Æ÷Á¾¾ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
JVP [POMD P 49 - 52]
  1) Jugular Vein Pressure
  2) Jugular Venous Pulse
...
GCT general care and treatment; germ-cell tumor; giant cell thyroiditis; giant cell tumor
HGPS hereditary giant platelet syndrome; Hutchinson-Gilford progeria syndrome
MGPS hereditary giant platelet syndrome
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CGC cerebral giant cell
FBGC Foreign Body Giant Cell
GT Giant
GAN Giant Axonal Neuropathy
GCA Giant Cell Arteritis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • benign giant cell tumor
    ¾ç¼º °Å´ë¼¼Æ÷ Á¾¾ç
    1. °ñÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. °ñÀÇ ¾ç¼º Á¾¾çÀÇ Çϳª·Î ³ë¾àÀÚ¿¡°Ô ¸¹À¸¸ç ¹ß»ý ºÎÀ§´Â Àå°ü°ñÀÇ °ñ´Ü¿¡ ¸¹ÀÌ ³ªÅ¸³­´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¿øÇü, ¹æÃßÇüÀÌ ÀÖ´Ù. ¼¼Æ÷ »çÀÌ¿¡ ÆÄ°ñ¼¼Æ÷¿Í À¯»çÇÑ °Å´ë¼¼Æ÷°¡ È¥ÀçÇÑ´Ù. 2. °ÇÃÊÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. º»·¡ Á¾¾çÀÌ ¾Æ´Ï¸ç, °áÁ¤¼º °ÇÃÊ¿°À» °¡¸®Å°¸ç °ÇÃÊÀÇ ¼¶À¯¼º Á¶Á÷±¸Á¾¿¡ Æ÷ÇԵȴÙ.
  • central giant cell
    °ñ³» °Å´ë ¼¼Æ÷
  • central giant cell tumor
    Á߽ɼº °Å´ë ¼¼Æ÷ ¾ÏÁ¾
  • disorder of blood platelet
    Ç÷¼ÒÆÇ Àå¾Ö
  • foreign body giant cell
    À̹° °Å´ë ¼¼Æ÷, À̹° °Å¼¼Æ÷
  • lingual benign giant cell tumor
    ¾ç¼º °Å´ë ¼¼Æ÷ ¼³ Á¾¾ç
  • multinucleated giant cell
    ´ÙÇÙ °Å´ë ¼¼Æ÷, °Å´ë ´ÙÇÙ ¼¼Æ÷, ´ÙÇÙ °Å¼¼Æ÷
  • platelet
    Ç÷¼ÒÆÇ
    1. °ñ¼ö¿¡ ÀÖ´Â °ÅÇÙ ¼¼Æ÷ÀÇ ÆÄÆíÀ¸·Î Á÷°æÀÌ 2-4 §­ Á¤µµ·Î ÇÙÀÌ ¾ø´Ù. Ç÷°ü ¼Õ»ó ½Ã Ç÷°ü ¼Õ»ó ºÎÀ§¸¦ ±â°èÀûÀ¸·Î Æä¼âÇϸç, Ç÷¼ÒÆÇ¿¡¼­ À¯¸®µÈ ¹°ÁúÀÌ Ç÷°üÀ» °­ÇÏ°Ô ¼öÃà½ÃÅ´À¸·Î½á ÁöÇ÷ÀÛ¿ëÀ» ÇÑ´Ù. ¶ÇÇÑ Ç÷¾× ÀÀ°í¿¡µµ °ü¿©ÇÑ´Ù. 2. ÀÛÀº ¿øÇüÁú ÆÇ ¸ð¾çÀ̰í, ÇÙÀÌ ¾ø±â ¶§¹®¿¡ ÁøÁ¤ÇÑ ÀǹÌÀÇ ¼¼Æ÷°¡ ¾Æ´Ï´Ù. À̵éÀº °ñ¼ö¿¡ ÀÖ´Â °Å´ë ÇÙ ¼¼Æ÷ÀÇ ¼¼Æ÷Áú Á¶°¢µéÀÌ ¶³¾îÁ®¼­ µÈ °ÍÀ¸·Î ¼øÈ¯ Ç÷¾× ³»¿¡´Â »ö±òÀÌ ¾ø´Ù.
  • platelet aggragating factor
    Ç÷¼ÒÆÇ ÀÀÁý ¿ä¼Ò, Ç÷¼ÒÆÇ ¾ÇÈ­ ÀÎÀÚ, Ç÷¼ÒÆÇ ¾ÇÈ­ ¿äÀÎ
    ¸é¿ª ±Û·ÎºÎ¸° E¿¡ °¨±¤µÈ È£¿°±â±¸¿¡¼­ÀÇ Ç׿ø ¹ÝÀÀ¿¡ ÀÇÇØ Ç÷¾× ³»¿¡ »ý¼ºµÈ ¹°Áú·Î¼­ Ç÷¼ÒÆÇÀ» ÀÀÁý½Ã۸ç, ¿°ÁõÀ» À¯¹ß½ÃŲ´Ù.
  • platelet concentrate
    Ç÷¼ÒÆÇ ³óÃà¾×
  • platelet fector III
    Ç÷¼ÒÆÇ Á¦ »ï ÀÎÀÚ
  • platelet transfusion
    Ç÷¼ÒÆÇ ¼öÇ÷
  • platelet-activating factor
    Ç÷¼ÒÆÇ Ȱ¼º ÀÎÀÚ
  • qualitative platelet defect
    Á¤»ó Ç÷¼ÒÆÇ °áÇÌÁõ, ÁúÀû Ç÷¼ÒÆÇ °áÇÔ
  • uninuclear giant cell
    ȬÇÙ °Å´ë ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
acquired platelet function defect <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines).
Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation.
(29 Dec 1997)
antigens, human platelet Human alloantigens expressed only on platelets, specifically on platelet membrane glycoproteins. These platelet-specific antigens are immunogenic and can result in pathological reactions to transfusion therapy.
(12 Dec 1998)
anti-platelet agents Medications that, like aspirin, reduce the tendency of platelets in the blood to clump and clot.
(12 Dec 1998)
receptors, platelet-derived growth factor Specific molecular sites or structures on cell membranes that react with platelet-derived growth factor, its analogs, or antagonists, to elicit or to inhibit the specific response of the cell to this factor. Pdgf binds with different affinities and specificities to two structurally related receptors, the alpha-receptor and the beta-receptor. Both of these receptors are transmembrane proteins with an intracellular, ligand-stimulatable protein kinase domain.
(12 Dec 1998)
medication, anti-platelet Platelet-blocking drugs. Drugs that, like aspirin, reduce the tendency of platelets in the blood to clump and clot.
(12 Dec 1998)
platelet <haematology> A discoid cell (3m diameter) found in large numbers in blood, important for blood coagulation and for haemostasis by repairing breaches (small breaks) in the walls of blood vessels.
Platelet _ granules contain lysosomal enzymes, dense granules contain ADP (a potent platelet aggregating factor) and serotonin (a vasoactive amine). They also release platelet-derived growth factor which presumably contributes to later repair processes by stimulating fibroblast proliferation.
Synonym: thrombocytes.
(09 Oct 1997)
platelet-activating factor <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis.
It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction.
Synonym: platelet-aggregating factor.
Acronym: PAF
(20 Sep 2002)
platelet activation A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable haemostatic plug.
(12 Dec 1998)
platelet actomyosin The contractile protein of platelets, responsible for clot retraction, platelet aggregation, and release of ADP and other biologic amines essential to platelet function.
Synonym: thrombosthenin.
(05 Mar 2000)
platelet adhesiveness The process whereby platelets adhere to something other than platelets, e.g., collagen, basement membranes, microfibrils, or other "foreign" surfaces.
(12 Dec 1998)
platelet-aggregating factor <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis.
It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction.
Synonym: platelet-aggregating factor.
Acronym: PAF
(20 Sep 2002)
platelet aggregation The attachment of platelets to one another. This clumping together can be induced by a number of agents (e.g., thrombin, collagen) and is part of the mechanism leading to the formation of a thrombus.
(12 Dec 1998)
platelet aggregation inhibitors Drugs or agents which antagonise or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
(12 Dec 1998)
platelet aggregation test A test of the ability of platelets to adhere to each other and hence form a haemostatic plug to prevent bleeding; failure to aggregate occurs in several conditions, e.g., thrombasthenia, Von Willebrand's disease, and following administration of aspirin, phenylbutazone, and indomethacin; the test is conducted by quantitating the decrease in turbidity that occurs in platelet-rich plasma following the in vitro addition of one or several platelet-aggregating agents (e.g., ADP, epinephrine, or serotonin).
(05 Mar 2000)
platelet basic protein <protein> Protein that is the precursor of connective tissue activating peptide III and _ thromboglobulin.
(18 Nov 1997)
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
giant platelet s. Bernard-Soulier s.
Ãâó: www.mercksource.com/pp/us/cns/cns_health_library.j...
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • giant
    °ÅÀÎ;À§ÀÎ;°Å´ëÇÑ
  • giant cactus
    Å« ¼±ÀÎÀå
  • giant panda
    ¹ÙµÏ°õ;ÀÚÀÌ¾ðÆ® ÆÒ´õ 9
  • giant planet
    ´ëÇ༺(¸ñ¼ºÇü Ç༺,¸ñ¼º,Å伺,õ¿Õ¼º,ÇØ¿Õ¼ºÀÇ ÃÑĪ)
  • giant power
    ´ÙÀ̳ʸ¶ÀÌÆ®ÀÇ ÀÏÁ¾
  • giant salom
    (½ºÅ°ÀÇ)´ëȸÀü(°æ±â)
  • giant star
    °Å¼º(Á÷°æ,±¤µµ,Áú·®)µîÀÌ ÇöÀúÇÏ°Ô Å« Ç×¼º
  • giant swing
    (öºÀÀÇ)´ëÂ÷·û 
  • giant(s) stride
    ȸÀü ±×³×
  • red giant
    Àû»ö °Å¼º(Ç¥¸é ¿Âµµ°¡ ³·°í ºÓ°Ô ºû³ª´Â Å« º°)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á